Martha Nowosielski1, Benedikt Wiestler, Georg Goebel, Markus Hutterer, Heinz P Schlemmer, Günther Stockhammer, Wolfgang Wick, Martin Bendszus, Alexander Radbruch. 1. From the Departments of Neurology (M.N., M.H., G.S.) and Medical Statistics, Informatics and Health Economics (G.G.), Innsbruck Medical University, Austria; the Department of Neurooncology (B.W., W.W.), Neurology Clinic and National Center for Tumor Diseases, and the Department of Neuroradiology (M.N., M.B., A.R.), University of Heidelberg; the Department of Neurology (M.H.), Regensburg Medical University; the Department of Radiology (H.P.S.), the Clinical Cooperation Unit Neurooncology (B.W., W.W.), and Department of Radiology, Neurooncologic Imaging (E012) (A.R.), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract
OBJECTIVE: This retrospective study analyzed whether the type of radiologic progression, classified according to contrast enhancement on MRI T1-weighted sequences and changes in T2-hyperintense signal, is relevant for outcome in patients with progressive glioblastoma (pGB) treated with bevacizumab. METHODS: MRI scans of 83 patients with pGB treated with bevacizumab were evaluated prior to and at disease progression. Based on initial decrease in and subsequent flare-up of contrast enhancement in T1 and 2 patterns of T2-hyperintense tumor progression, progression types (PTs) were categorized as cT1 flare-up, T2-diffuse, T2-circumscribed, or primary nonresponder. Overall survival (OS), survival from start of bevacizumab therapy (OS_Bev), survival after bevacizumab failure (OS_PostBev), time from initial diagnosis until initiation of bevacizumab therapy (StartBevT), and time to bevacizumab progression were evaluated using Kaplan-Meier curves, log-rank test, and Cox regression analyses. RESULTS: The time observed for development of a T2-diffuse (n = 15) or a cT1 flare-up (n = 35) progression was longer than for progression in primary nonresponders (n = 16) or T2-circumscribed progression (n = 17). The T2-diffuse PT showed longer OS, OS_Bev, OS_PostBev, and StartBevT compared to the other PTs. Postprogression therapy tended to be relevant only for patients with a T2-circumscribed PT. CONCLUSIONS: Radiologic PTs following bevacizumab treatment failure show differences in time to development and are related to outcome. We therefore hypothesize that these PTs reflect a different glioma biology, including differential resistance mechanisms to bevacizumab, and may be associated with different responses to postprogression therapy.
OBJECTIVE: This retrospective study analyzed whether the type of radiologic progression, classified according to contrast enhancement on MRI T1-weighted sequences and changes in T2-hyperintense signal, is relevant for outcome in patients with progressive glioblastoma (pGB) treated with bevacizumab. METHODS: MRI scans of 83 patients with pGB treated with bevacizumab were evaluated prior to and at disease progression. Based on initial decrease in and subsequent flare-up of contrast enhancement in T1 and 2 patterns of T2-hyperintense tumor progression, progression types (PTs) were categorized as cT1 flare-up, T2-diffuse, T2-circumscribed, or primary nonresponder. Overall survival (OS), survival from start of bevacizumab therapy (OS_Bev), survival after bevacizumab failure (OS_PostBev), time from initial diagnosis until initiation of bevacizumab therapy (StartBevT), and time to bevacizumab progression were evaluated using Kaplan-Meier curves, log-rank test, and Cox regression analyses. RESULTS: The time observed for development of a T2-diffuse (n = 15) or a cT1 flare-up (n = 35) progression was longer than for progression in primary nonresponders (n = 16) or T2-circumscribed progression (n = 17). The T2-diffuse PT showed longer OS, OS_Bev, OS_PostBev, and StartBevT compared to the other PTs. Postprogression therapy tended to be relevant only for patients with a T2-circumscribed PT. CONCLUSIONS: Radiologic PTs following bevacizumab treatment failure show differences in time to development and are related to outcome. We therefore hypothesize that these PTs reflect a different glioma biology, including differential resistance mechanisms to bevacizumab, and may be associated with different responses to postprogression therapy.
Authors: Benjamin M Ellingson; Albert Lai; Huytram N Nguyen; Phioanh L Nghiemphu; Whitney B Pope; Timothy F Cloughesy Journal: Clin Cancer Res Date: 2015-04-21 Impact factor: 12.531
Authors: N Bahrami; D Piccioni; R Karunamuni; Y-H Chang; N White; R Delfanti; T M Seibert; J A Hattangadi-Gluth; A Dale; N Farid; C R McDonald Journal: AJNR Am J Neuroradiol Date: 2018-04-05 Impact factor: 3.825
Authors: Rifaquat Rahman; Kelly Hempfling; Andrew D Norden; David A Reardon; Lakshmi Nayak; Mikael L Rinne; Rameen Beroukhim; Lisa Doherty; Sandra Ruland; Arun Rai; Jennifer Rifenburg; Debra LaFrankie; Brian M Alexander; Raymond Y Huang; Patrick Y Wen; Eudocia Q Lee Journal: Neuro Oncol Date: 2014-06-23 Impact factor: 12.300
Authors: Elizabeth R Gerstner; Xiaobu Ye; Dan G Duda; Michael A Levine; Tom Mikkelsen; Thomas J Kaley; Jeffrey J Olson; Burt L Nabors; Manmeet S Ahluwalia; Patrick Y Wen; Rakesh K Jain; Tracy T Batchelor; Stuart Grossman Journal: Neuro Oncol Date: 2015-05-24 Impact factor: 12.300
Authors: David Cachia; Nabil A Elshafeey; Carlos Kamiya-Matsuoka; Masumeh Hatami; Kristin D Alfaro-Munoz; Jacob J Mandel; Rivka Colen; John F DeGroot Journal: J Neurooncol Date: 2017-07-12 Impact factor: 4.130
Authors: Patrick Y Wen; Timothy F Cloughesy; Benjamin M Ellingson; David A Reardon; Howard A Fine; Lauren Abrey; Karla Ballman; Martin Bendszuz; Jan Buckner; Susan M Chang; Michael D Prados; Whitney B Pope; Alma Gregory Sorensen; Martin van den Bent; Wai-Kwan Alfred Yung Journal: Neuro Oncol Date: 2014-10 Impact factor: 12.300